CHICAGO--31 Mar--PRNewswire-AsiaNet/InfoQuest Reductions seen as soon as three days and out to 450 days in patients who received either bare metal or drug-eluting stents The investigational antiplatelet drug prasugrel plus aspirin produced a marked and highly statistically significant reduction in the risk of coronary stent thrombosis (ST) - a major concern for physicians and patients with potentially fatal consequences - in patients who received a stent as compared to standard therapy with clopidogrel (Plavix(R)) plus aspirin (1.13 percent vs. 2.35 percent, p